1069C85

1069C85 is a **novel synthetic tubulin-binding agent** developed as an **anti-cancer small molecule** intended to overcome **multidrug resistance** typical of certain cytotoxic drugs like the vinca alkaloids. It acts by binding to the **colchicine site on tubulin**, disrupting microtubule formation and inhibiting cell division. The drug was given **orally**, demonstrated promising cytotoxicity against multidrug-resistant human tumor cell lines, and was advanced to phase I clinical trials. However, development was discontinued due to unpredictable and severe neurotoxicity, including a fatal case in the phase I study, preventing safe phase II evaluation[1][3][5].

Other names

methyl N-[6-(3,4,5-trimethoxybenzyloxy)imidazo(1,2b)-pyridazin-2-yl] carbamate